Subcutaneous Levetiracetam Administration in Latino Patients on Home Care
American Journal of Hospice and Palliative Medicine® · 2024
DOI: 10.1177/10499091231212450 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift American Journal of Hospice and Palliative Medicine®, 2024. Verfasst von Laura Cuellar-Valencia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universidad de La Sabana, Bogotá DC, Colombia. Hauptthemen laut MEDLINE: Anticonvulsants, Hispanic or Latino, Home Care Services, Levetiracetam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Ambulante Pflege
Abstract (Originalsprache)
Background
Levetiracetam has a favorable pharmacology profile to be used subcutaneously. However, its subcutaneous use is still considered off-label as this is beyond its license. The evidence base for its safety, tolerability, and efficacy is limited to observational studies.
Objectives
To report the safety and efficacy of subcutaneous levetiracetam in Latino patients on home care.
Design
Observational retrospective case series study. Subjects: Consecutive sample of Latino adults with life-limiting illnesses.
Methods
A case series framework with 4 domains (selection, ascertainment, causality, and reporting) to ensure reporting quality was used. Additionally, 8 relevant outcomes established in a previous comprehensive review, were collected and reported. Adverse reactions were documented using the Common Terminology Criteria for Adverse Events.
Results
Fifteen Latino patients with oncological and non-oncological diagnoses received subcutaneous levetiracetam for a mean of 21 days on home care. Levetiracetam was most frequently initiated subcutaneously due to loss of the oral route. The average dosage of subcutaneous levetiracetam was 1200 mg. Only 1 patient required a dose adjustment, and only 2 patients experienced a total of 5 seizures during the therapy trial. No adverse reactions were reported.
Conclusions
Subcutaneous levetiracetam appears to be effective and safe. This case series of Latino patients in home care expands the evidence of its use in the home care setting. The preliminary data reported by now on multiple case series warrants robust trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Universidad de La Sabana, Bogotá DC, Colombia.
- Colombian National Cancer Institute, Bogotá DC, Colombia.
- Forja home care IPS, Bogotá DC, Colombia.
- Faculty of Medicine, Universidad del Bosque, Bogotá DC, Colombia.
ORCID-Profile: Laura Cuellar-Valencia, Juan Esteban Correa-Morales
Zitieren
APA
Cuellar-Valencia, L., Claros-Hulbert, A., Ortegon, A., Pino, J., Velandia, L., & Correa-Morales, J. E. (2024). Subcutaneous Levetiracetam Administration in Latino Patients on Home Care. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/10499091231212450
Vancouver
Cuellar-Valencia L, Claros-Hulbert A, Ortegon A, Pino J, Velandia L, Correa-Morales JE. Subcutaneous Levetiracetam Administration in Latino Patients on Home Care. American Journal of Hospice and Palliative Medicine®. 2024. doi:10.1177/10499091231212450
BibTeX
@article{CuellarValencia2024,
author = {Cuellar-Valencia, Laura and Claros-Hulbert, Angelica and Ortegon, Adriana and Pino, Juliana and Velandia, Laura and Correa-Morales, Juan Esteban},
title = {Subcutaneous Levetiracetam Administration in Latino Patients on Home Care},
journal = {American Journal of Hospice and Palliative Medicine®},
year = {2024},
doi = {10.1177/10499091231212450}
}
EUVIMED